Immunome Inc. reported its full‑year 2025 financial results, posting a net loss of $212.4 million, a narrowing from the $293.0 million loss in 2024. Collaboration revenue fell to $6.9 million from $9.04 million, while research and development expenses rose to $177.3 million and general and administrative expenses increased to $43.8 million.
The company’s cash and cash equivalents stood at $653.5 million as of December 31, 2025, bolstered by a $432.4 million financing in December. The stronger cash position extends the company’s runway to 2028, providing a financial cushion for continued pipeline development.
A key driver of the results is the positive topline data from the Phase 3 RINGSIDE trial of varegacestat, which was announced in December 2025. The trial met its primary endpoint with an 84 % reduction in the risk of disease progression or death and a 56 % objective response rate versus 9 % on placebo. The company plans to submit a New Drug Application in the second quarter of 2026.
Other pipeline activity includes the ongoing Phase 1 study of IM‑1021, where early data show objective responses in B‑cell lymphoma patients, and the planned submission of INDs for three solid‑tumor antibody‑drug conjugate programs in 2026.
CEO Clay B. Siegall said, “Immunome made substantial progress in 2025. The positive Phase 3 RINGSIDE results represent a significant milestone for patients living with desmoid tumors and will support our planned NDA submission for varegacestat in the second quarter of 2026.” He added, “We are focused on the regulatory, manufacturing, and commercial readiness activities necessary to position the program for approval and launch.” Regarding the ADC pipeline, Siegall noted, “Over the course of 2026, we expect to submit INDs for three differentiated solid tumor ADCs. These programs have substantial potential to benefit cancer patients, and we intend to rapidly advance them.”
The earnings report underscores Immunome’s continued investment in R&D, reflected in the rise of R&D expenses, while the narrowing net loss signals improving cost discipline. The strong Phase 3 results and robust cash position position the company to pursue regulatory milestones and expand its oncology portfolio over the next few years.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.